People with MS experience significant changes in cognition more than a year before significant physical decline is evident, a ...

The eSDMT enables frequent remote cognitive assessments for pwMS, shifting from cross-sectional to longitudinal evaluation frameworks. The study showed strong concurrent validity and test-retest ...

Researchers have studied MS measurement tools for their effectiveness in predicting employment status. They compared the Expanded Disability Status Scale, the Multiple Sclerosis Functional Composite, ...

Qure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease. Huntington’s disease is an inherited condition in which nerve cells in ...

UniQure shares tripled, to $41.27, in early Wednesday trading after the company said it had positive topline results for a Phase I/II study of AMT-130 for the treatment of Huntington's disease, and ...

Researchers say a multiple sclerosis drug meant to slow physical disability also shows promise in improving mental acuity in people who are living with secondary progressive MS, an advanced form of ...

The subjects were 141 patients who had sustained TBIs and who were evaluated at the North Carolina Neuropsychiatry Clinics in Chapel Hill and Charlotte during a 2-year period from March 2003 through ...

Treatment with ozanimod (Zeposia) led to clinically meaningful improvement in cognitive processing speed among people with early relapsing multiple sclerosis (RMS), an ad hoc interim analysis of the ...